UBE2Q2 promotes tumor progression and glycolysis of hepatocellular carcinoma through NF-κB/HIF1α signal pathway
Open Access
- 20 January 2025
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 48 (3) , 637-654
Abstract
Purpose Metabolic reprogramming, particularly the Warburg effect, plays a crucial role in the onset and progression of tumors. The ubiquitin-conjugating enzyme E2 Q2 (UBE2Q2) has been identified overexpressed in hepatocellular carcinoma (HCC). Our aim was to determine if UBE2Q2 plays a role in regulating glycolysis, contributing to the carcinogenesis of HCC. Methods Bioinformatics analysis, western blot and qPCR were used to detect the expression of UBE2Q2. Functional experiments, proteomics analysis and subcutaneous tumors were constructed to find the biological function of UBE2Q2 in HCC. Co-immunoprecipitation, western blot and ubiquitination assays were used to identify the mechanisms involved. Results We found a significant association between high UBE2Q2 expression and poor prognosis in HCC patients. Functionally, UBE2Q2 was shown to advance tumor progression in HCC through both in vitro assays and in vivo assessments. Proteomics analysis and glycolysis stress tests corroborated an increase in glycolytic activity due to UBE2Q2. Our findings reveal that UBE2Q2 augments glycolysis by boosting the transcription levels of hypoxia-inducible factor 1α (HIF1α), primarily through the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. At the molecular level, UBE2Q2 interaction with baculoviral IAP repeat-containing 2 (cIAP1) orchestrates the K63-linked ubiquitination of receptor-interacting serine/threonine-protein kinase 1 (RIP1), which in turn, activates the NF-κB signaling pathway. Conclusions Our investigation reveals that UBE2Q2 regulates the glycolysis in HCC through modulation of the NF-κB/HIF1α signaling pathway, pinpointing UBE2Q2 as a promising therapeutic target for the disease. Graphical abstractKeywords
Funding Information
- Research Fund of the Health Commission of Hubei Province (WJ2021M255)
- Cancer research and translational platform project of Zhongnan Hospital of Wuhan University (ZLYNXM202004)
- Translational Medicine and Interdisciplinary Research Joint Fund Project of Zhongnan Hospital of Wuhan University (ZNJC201918)
This publication has 42 references indexed in Scilit:
- Ginsenoside Rh4 inhibits inflammation-related hepatocellular carcinoma progression by targeting HDAC4/IL-6/STAT3 signalingMolecular Genetics and Genomics, 2023
- Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under HypoxiaHepatology, 2021
- Non-canonical Targets of HIF1a Impair Oligodendrocyte Progenitor Cell FunctionCell Stem Cell, 2020
- The Worst from Both Worlds: cHCC-ICCCancer Cell, 2019
- Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signalingCell Death & Differentiation, 2017
- HIF-1α pathway: role, regulation and intervention for cancer therapyActa Pharmaceutica Sinica B, 2015
- IAPs: Guardians of RIPK1Cell Death & Differentiation, 2011
- c‐IAP1 and UbcH5 promote K11‐linked polyubiquitination of RIP1 in TNF signallingThe EMBO Journal, 2010
- Overexpression of the novel human gene, UBE2Q2, in breast cancerCancer Genetics and Cytogenetics, 2010
- The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysisNature, 1999